Simplify-1: A phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor–naïve patients with myelofibrosis

Journal of Clinical Oncology

Volumn 35, Issue 34, 2017, Pages 3844-3850

  Mesa, Ruben A ^a   Kiladjian, Jean Jacques ^b   Catalano, John V ^c   Devos, Timothy ^d   Egyed, Miklos ^e   Hellmann, Andrzei ^f   McLornan, Donal ^g   Shimoda, Kazuya ^h   Winton, Elliott F ⁱ   Deng, Wei ^j   Dubowy, Ronald L ^j   Maltzman, Julia D ^j   Cervantes, Francisco ^l   Gotlib, Jason ^k  

^a MAYO CLINIC   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Kaposi Mor Teaching Hospital   (Hungary)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF MIYAZAKI   (Japan)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j GILEAD SCIENCES   (United States)

^k STANFORD CANCER INSTITUTE   (United States)

^l UNIVERSITY OF BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; MOMELOTINIB; RUXOLITINIB; BENZAMIDE DERIVATIVE; JANUS KINASE INHIBITOR; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; ADULT; AGED; ANEMIA; AORTIC DISSECTION; ARTICLE; COMA; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; HEAD INJURY; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MELENA; MESENTERIC VEIN THROMBOSIS; MIDDLE AGED; MOTOR NEUROPATHY; MULTICENTER STUDY; MYELOFIBROSIS; NAUSEA; NEURALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPSIS; SPLEEN; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MORTALITY; MYELOID METAPLASIA; PATHOLOGY; PATIENT SAFETY; PROGNOSIS; RETREATMENT; RISK ASSESSMENT; SURVIVAL ANALYSIS;

AGED; BENZAMIDES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JANUS KINASE INHIBITORS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATIENT SAFETY; PRIMARY MYELOFIBROSIS; PROGNOSIS; PYRAZOLES; PYRIMIDINES; RETREATMENT; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85035815718     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.73.4418     Document Type: Article

References (18)

1. Pardanani A, Gotlib JR, Jamieson C, et al: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789-796, 2011
2. Levine RL, Pardanani A, Tefferi A, et al: Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7:673-683, 2007
3. Delhommeau F, Jeziorowska D, Marzac C, et al: Molecular aspects of myeloproliferative neoplasms. Int J Hematol 91:165-173, 2010
4. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379-2390, 2013
5. Pardanani A: JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 22: 23-30, 2008
6. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787-798, 2012
7. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
8. Pardanani A, Lasho T, Smith G, et al: CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23:1441-1445, 2009
9. Tyner JW, Bumm TG, Deininger J, et al: CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115: 5232-5240, 2010
10. Asshoff M, Petzer V, Warr MR, et al: Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 129:1823-1830, 2017
11. Gupta V, Mesa RA, Deininger MWN, et al: A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 102:94-102, 2017
12. Harrison CN, Vannucchi AM, Platzbecker U, et al: Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). J Clin Oncol 35, 2017 (abstr 7001; suppl)
13. Tefferi A, Thiele J, Orazi A, et al: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097, 2007
14. Barosi G, Mesa RA, Thiele J, et al: Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22:437-438, 2008
15. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-2901, 2009
16. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982
17. Tefferi A, Cervantes F, Mesa R, et al: Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122: 1395-1398, 2013
18. Abdelrahman RA, Begna KH, Al-Kali A, et al: Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol 169:77-80, 2015